Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous Vaccination With mRNA COVID-19 Vaccine and Other Vaccines in Young Children
NCT06038617Phase 4Completed
- Sponsor
- Duke University
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mRNA COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Duke University. Primary endpoint: Number of Participants With Fever Following Vaccination at 2 days. Started Oct 2023; status: completed.
02
Drugs
mRNA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06038617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038617.